UnknownNot Applicable

Bedside vs. Standard Microbiological Blood Culture Diagnostics - BEMIDIA Study

Germany500 participantsStarted 2016-11

Plain-language summary

With a completely bedside blood culture diagnostics system (BACTEC blood culture system in combination with the Accelerate ID/AST System) it is possible to optimize the initial antimicrobial therapy in patients with sepsis and septic shock. Prospective observational, open-label mono-center study to compare a completely bedside blood culture diagnostics system (BACTEC blood culture system in combination with the Accelerate ID/AST System and Curetis Univero System) with standard blood culture diagnostics in patients with sepsis or septic shock.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with a new diagnosed sepsis or septic shock: emergency department, operating theatre, intensive care unit and planed blood culture diagnostics. * informed written consent Exclusion Criteria: * Pediatric patients (\< 18 Years) * DNR-order

What they're measuring

Time to a significant change of antimicrobial therapy from the time of the diagnosis of sepsis or septic shock

Timeframe: Nov. 2016 - Nov. 2017

Trial details

NCT IDNCT03000049

SponsorUniversity Medicine Greifswald

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2017-07

Contact for this trial

Matthias Gründling, MD

gruendli@uni-greifswald.de

View on ClinicalTrials.gov More Sepsis Septic Shock trials